BioSpace News Archive

NAVC Veterinary Meeting and Expo booth #1026 —June 6, 2021—, Antech Diagnostics announced new data and innovative advances to several core diagnostic tests to help veterinarians find disease faster and more efficiently than traditional diagnostics allow.

Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study

AnHeart Therapeutics Co., Ltd together with Innovent Biologics, Inc., jointly announce a presentation of a scientific poster entitled “Preliminary results from TRUST: A phase II clinical study to investigate Taletrectinib in treating patients with ROS1 fusion positive non-small cell lung cancer ” which summarizes initial data from its ongoing trial of taletrectinib at the American Society of Clinical Oncology 2021 Annual Meeting.

Innovent Biologics, Inc together with AnHeart Therapeutics Co., Ltd jointly announced a presentation of a scientific poster entitled “Preliminary results from TRUST: A phase II clinical study to investigate Taletrectinib in treating patients with ROS1 fusion positive non-small cell lung cancer " which summarizes initial data from its ongoing trial of taletrectinib at the American Society of Clinical Oncology 2021 Annual Meeting.

iTEAR®100 is an FDA-cleared external neurostimulation device that increases acute tear production.

Ascletis Pharma Inc. announces that China National Medical Products Administration has approved the Investigational New Drug application for its drug candidate ASC42 to conduct clinical trials for chronic hepatitis B indication.

Covetrus®, a global leader in animal-health technology and services, announced an enhancement to their leading practice management software to help veterinary clinics compete online and deliver more complete healthcare.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced with HUTCHMED that the results of the Phase 1b study in advanced colorectal cancer patients were released in an poster discussion at the 2021 American Association for Clinical Oncology Annual Meeting.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase Ia/Ib study of IBI110 were released in a poster presentation at the American Society of Clinical Oncology Annual Meeting 2021.

On June 4, 2021, OriginCell Therapeutics Co., Ltd., together with Lishui Central Hospital affiliated to Zhejiang University and Shanghai Changzheng Hospital, presented the updated data from the on-going trial of Ori-CAR-001, a GPC3 CAR-T cell therapy for the treatment of relapsed/refractory hepatocellular carcinoma, at the 2021 annual meeting of American Society of Clinical Oncology.